Canine Comparative Oncology and Genomics Consortium And the Pfizer-CCOGC Biospecimen Repository Announce the Availability of Canine Biospecimens for Scientific Study

Rockville, MD – Canine cancer biospecimens are now available to be released for scientific research through the Canine Comparative Oncology and Genomics Consortium (CCOGC) and the Pfizer-CCOGC Biospecimen Repository.

Patient sample sets from canine cancer patients have been collected to build the repository and they are now available to help researchers further the investigation into the inner workings of cancer in many breeds, as well as facilitate investigation into tumor types with broad translational relevance that can benefit both human and veterinary patients.

Seven spontaneously arising cancer histologies (osteosarcoma, lymphoma, melanoma, pulmonary tumors, mast cell tumor, soft tissue sarcomas, hemangiosarcom) are currently banked.  Samples from each patient include: tumor tissue, normal tissue, serum, plasma, urine, whole blood, DNA, and RNA.

In addition, the CCOGC has an established infrastructure for prospective sample collection should the banked samples not meet your research needs.

For more information about CCOGC, applying for repository samples, or inquiring about prospective tissue collections, please visit our website at or contact us at

CCOGC Background

Formed in 2004, the Canine Comparative Oncology and Genomics Consortium (CCOGC) is a group of veterinary and human medical oncologists, pathologists, surgeons, geneticists, and cellular and molecular biologists who share the common goals of facilitating collaborations across disciplines, focusing on the problem of cancer in dogs. Priorities of the CCOGC include advocacy for the field of Comparative Oncology, expansion of available canine specific research reagents, and the development of a biospecimen repository.

In 2007 sample collection began at veterinary institutions, with a focus on collecting three histologies of interest in the field of comparative oncology (osteosarcoma, lymphoma, melanoma). The initial goal was to collect, annotate and optimally collect sample sets from naïve canine cancer patients. In 2008, collection of four additional histologies (pulmonary tumors, mast cell tumor, soft tissue sarcomas, hemangiosarcoma) were added to the repository based on their relevance to canine and human cancer.

Standard operating procedures for tissue/sample collection and storage have been established to maximize consistency and are subject to annual review. Informed owner consent and IACUC approval has been obtained prior to collection and samples have been de-identified at the collecting site. The biospecimen repository houses tumor tissue, normal tissues, serum, plasma, peripheral blood mononuclear cell preparations, genomic DNA, RNA and urine samples. Each case in the repository is represented by tumor and normal tissue, collected and processed in ethanol and two frozen formats (flash frozen and OCT embedded). The repository follows many aspects of the organization and structure of the proposed National Biospecimen Network Blueprint. A sample shipping and collection database (Tissue Tracker) is used for real time connection between CCOGC collection sites and the central physical bank (Pfizer-CCOGC Biospecimen Repository) housed in Frederick, MD. Patient clinical information is contemporarily collected and logged as part of the biorepository effort and is available along with the samples.

Comments are closed.